poisar

Stocks · News reference

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

Vandana Singh

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABTBBNXDXCMMMEDPODDTNDM
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  4. Delveinsight

    Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight

    The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.

    MDTBSXABTNPCEINSP
  5. Robbins Llp

    BBNX Stockholders Have Rights – If You Lost Money Investing in Beta Bionics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

    Robbins LLP announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company downplayed FDA Form 483 concerns in October 2025, claiming issues were minor, but the FDA's February 2026 warning letter revealed serious malfunctions causing dangerous insulin overdoses. BBNX stock plummeted from $31.99 to $12.89 per share between January and February 2026. Investors who suffered losses during the class period (July 30, 2025 - February 24, 2026) may be eligible to recover damages.

    BBNX